Table 3.
Univariate Analysis of Death and ICU Admission*
| Variable | ICU Admission (N = 61) | Death 30 d (N = 57)† | Death 1 y (N = 53)† | |||
|---|---|---|---|---|---|---|
| Y (N = 18) Number (%) | N (N = 43) Number (%) | Y (N = 8) Number (%) | N (N = 49) Number (%) | Y (N = 19) Number (%) | N (N = 34) Number (%) | |
| Age >60 | 5 (28%) | 17 (40%) | 4 (50%) | 17 (35%) | 8 (42%) | 12 (35%) |
| Female gender | 7 (39%) | 20 (47%) | 2 (25%) | 25 (51%) | 6 (32%) | 20 (59%) |
| Diabetes | 4 (22%) | 9 (21%) | 2 (25%) | 11 (22%) | 4 (21%) | 9 (26%) |
| Hazardous alcohol | 7 (39%) | 11 (26%) | 3 (38%) | 15 (31%) | 4 (21%) | 12 (35%) |
| Malignancy | 3 (17%) | 9 (21%) | 2 (25%) | 8 (16%) | 6 (32%) | 4 (12%) |
| Chronic lung disease | 10 (56%) | 22 (51%) | 5 (65%) | 24 (49%) | 10 (53%) | 19 (56%) |
| Transplant | 1 (6%) | 2 (5%) | 0 (0%) | 3 (6%) | 0 (0%) | 3 (9%) |
| HIV | 0 (0%) | 2 (5%) | 0 (0%) | 2 (4%) | 0 (0%) | 2 (6%) |
| Immunosuppressive medication | 6 (33%) | 9 (21%) | 3 (38%) | 11 (22%) | 7 (37%) | 7 (21%) |
| Indigenous | 8 (44%) | 15 (35%) | 2 (25%) | 21 (43%) | 7 (37%) | 15 (44%) |
| Cutaneous disease | 0 (0%) | 8 (19%) | 0 (0%) | 8 (16%) | 0 (0%) | 3 (9%) |
| Pulmonary disease | 12 (67%) | 30 (70%) | 5 (65%) | 35 (71%) | 16 (84%) | 24 (71%) |
| Disseminated disease | 5 (28%) | 4 (9%) | 3 (38%) | 5 (10%) | 3 (16%) | 5 (15%) |
| Remote | 8 (44%) | 10 (23%) | 2 (25%) | 16 (33%) | 7 (37%) | 10 (29%) |
| Immunocompromised | 6 (33%) | 16 (37%) | 3 (38%) | 17 (35%) | 10 (53%) | 10 (29%) |
| Nocardia isolate resistant to TMP-SMX | 2 (11%) | 4 (9%) | 1 (13%) | 5 (10%) | 2 (11%) | 3 (9%) |
Abbreviations: CNS, central nervous system; HIV; human immunodeficiency virus; ICU, intensive care unit; TMP-SMX, trimethoprim-sulfamethoxazole.
*Associations between categorical variables measured using Fisher’s exact test.
†Numbers in these columns relate to cases where data was available. Four patients were lost to follow up by 30 days, and 8 patients were lost to follow up by 1 year. Note: P > .05 in each instance.